

1103326-0798

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Corswant et al.
Serial No. : 10/553,275
Filed : October 13, 2005
For : New Non-Ionic Surfactants for Solubilizing Poorly Soluble Molecules
Examiner : TBA
Group Art Unit : TBA

Certificate of Mailing Under 37 C.F.R. § 1.8	
I hereby certify that this paper is being deposited with the United States Postal Service as first class mail on the date indicated below in an envelope addressed to: Assistant Commissioner for Patents, Box 1450, Alexandria, VA 22313-1450	
Andrew Fessak	48,528
Agent Name	PTO Reg. No.
<i>Andrew Fessak</i>	<i>11/16/05</i>
Signature	Date of Signature

Mail Stop PCT
Commissioner for Patents
Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Applicant submits this communication in compliance with 37 C.F.R. §§1.56, 1.97 and 1.98. Favorable consideration of the document cited on the attached Form PTO/SB/08A is respectfully requested.

The referenced application is the U.S. national stage application of international application no. PCT/SE2004/000572, filed April 13, 2004 (the "PCT application"). The documents identified on the attached Form PTO/SB/08A include documents cited in the specification or the International Search Report ("ISR") which issued in connection with the PCT application. Copies of the published PCT application, i.e., International Publication

Number WO 2004/089869, and the ISR were previously submitted on October 13, 2005 with the national stage application transmittal documents.

Applicants have identified EP 17,059, published in the German language, and US 4,366,151 on attached Form PTO/SB/08A. Both of these patents are cited in the ISR of the PCT application, and both documents are members of the same patent family. Accordingly, Applicants are not providing a separate translation of EP 17,059.

Copies of Cited U.S. Patent Documents are Not Provided

As announced in the Official Gazette of August 5, 2003, the requirement under 37 CFR 1.98(a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC 371 after June 30, 2003 has been waived.

Accordingly, copies of the U.S. patents and/or published patent applications cited on the attached Form PTO/SB/08A are not provided with this Information Disclosure Statement.

Time of Transmittal of Information Disclosure Statement

This Information Disclosure Statement is being filed under 37 C.F.R. §1.97(b)(3) before the mailing date of the first Office Action on the merits and, therefore, no fee should be due. However, if any fee is required, the Assistant Commissioner is authorized to charge such fee to Deposit Account No. 23-1703.

Dated: NOV. 16, 2005

Respectfully submitted,



Andrew Fessak
Reg. No. 48,528
Customer No. 007470
White & Case LLP
Direct Dial: (212) 819-8437

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/553,275
				Filing Date	October 13, 2005
				First Named Inventor	Corswant
				Art Unit	TBA
Examiner Name	TBA				
Sheet	1	of	1	Attorney Docket Number	1103326-0798

U.S. PATENT DOCUMENTS					
Examiner Initials [*]	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear
		US-6,365,637	Apr. 2, 2002	Zirnstein et al.	
		US-4,366,151	Dec. 28, 1982	Oppenlaender et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials [*]	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		EP 17,059 B1	Nov. 25, 1981	Oppenlaender et al.		

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials [*]	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		LORENZ, W. et al., National Library of Medicine (NLM), file Medline, Medline accession no. 6177219.	
		STN International, file CAlplus, CAlplus accession no. 1999:431639, Document no. 131:86938.	
		DATABASE WPI, Week 199624, Derwent Publications Ltd., London, GB, Class B07, AN 1996-233354 & JP 80-89263 A.	
		DATABASE WPI, Week 198422 Derwent Publications Ltd., GB; Class A97, AN 1984-136506 & JP 59-069135A.	
		DATABASE WPI, Week 199538 Derwent Publications Ltd., London GB; Class D16, AN 1995-287977 & JP 71-84672A.	
		"The Theory and Practice of Industrial Pharmacy" 2 nd ed., Lea & Febiger, 1976, p. 108-111.	
		LORENTZ et al., "Agents and Actions", Vol. 12, 1/2, 1982, p. 64-80.	
		VULFSON, "Novel Surfactants", Holmberg editor, Marcel Dekker, 1988, p. 279-97.	
		YALKOWSKY, "Solubility & Solubilization in Aqueous Media", American Chemical Society and Oxford University Press, 1999, p. 312-320.	
		"Surface Active Agents (non-ionic)- Determination of Polyethylene Glycols and Non-Ionic Active Matter (adducts)- Weibull Method", International Standard Organization, ISO-2268:1972(E).	
		US Pharmacopeia 24, 2000, p. 10.	
		CORSWANT et al., "Triglyceride Based Microemulsion...", J. Pharm. Sci., 1998, 87(2), p. 200-8.	
		MOSHARRAF and NYSTRÖM, "The Effect of Particle...", Int. J. Pharm., 1995, 122, p. 35-47.	
		ÖSTH, Karin, Thesis: The Horizontal Ussing Chamber Method in Studies of Nasal Drug Delivery, 2002, Faculty of Pharmacy, Uppsala University; and attached papers: Paper I: ÖSTH et al., J. Pharm. Sci., vol. 91, no. 5, May 2002 Paper II: ÖSTH et al., J. Controlled Release, 83, (2002), 377-388 Paper III: ÖSTH et al., "Uptake of ovalbumin-conjugated starch microparticles by pig respiratory nasal mucosa <i>in vitro</i> " (manuscript submitted for publication) Paper IV: ÖSTH et al., "Correlation between epithelial toxicity and surfactant structure derived from studies of polyoxyethylene oxide and their effects on Caco-2 cells and pig nasal mucosa" (manuscript)	
Examiner Signature		Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.